Curcumae Ameliorates Diethylnitrosamine-Induced Hepatocellular Carcinoma via Alteration of Oxidative Stress, Inflammation and Gut Microbiota

Yunyan Zhang,Xuelian Li,Xinghua Li

DOI: https://doi.org/10.2147/JIR.S330499

IF: 4.5

2021-10-27

Journal of Inflammation Research

Abstract:Yunyan Zhang, 1 Xuelian Li, 2 Xinghua Li 3 1 Department of Laboratory Medicine, The First People's Hospital of Lianyungang City, Lianyungang City, Jiangsu, 222002, People's Republic of China; 2 Department of Laboratory Medicine, The Fourth People's Hospital of Lianyungang City, Lianyungang City, Jiangsu, 222002, People's Republic of China; 3 Department of Blood Transfusion, The First People's Hospital of Lianyungang City, Lianyungang City, Jiangsu, 222002, People's Republic of China Correspondence: Xinghua Li Department of Blood Transfusion, The First People's Hospital of Lianyungang City, Lianyungang City, Jiangsu, 222002, People's Republic of China Email Background: Nonalcoholic fatty liver disease (NAFLD) increased the risk factor of hepatocellular carcinoma (HCC). NAFLD induces the hepatic-related cancer deaths mostly in middle-aged men. NAFLD enhanced the inflammatory reaction and oxidative stress in the hepatic tissue. Curcumae exhibited the anti-inflammatory and antioxidant effects. In this study, we made an attempt to scrutinize the protective effect of curcumae on obesity-induced HCC via alteration of inflammation, oxidative stress and gut microbiota. Methods: The rats used in this experiment were Wistar rats, 100 mg/kg intraperitoneal injection of diethylnitrosamine (hepatic carcinogen) was used at 2 weeks. After 6 weeks of the experimental study, the rats were randomly divided into high-fat diet (HFD) with or without curcumae-treated group rats and received the treatment for 22 weeks. Hepatic, non-hepatic, cardiac, antioxidant, pro-inflammatory and inflammatory were estimated at the end of the study. The stools of the experimental rats were collected for estimating the gut microbiota. Results: Curcumae-treated group rats exposed reduction of the hepatic nodules in hepatic tissue. Curcumae significantly (P< 0.001) diminished the level of hepatic parameters and antioxidant parameters in the serum. Curcumae significantly (P< 0.001) suppressed the pro-inflammatory cytokines level, viz. interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), interleukin-2 (IL-2), interleukin-7 (IL-7) and augmented the level of interleukin-10 (IL-10) in the serum and hepatic tissue. Curcumae significantly (P< 0.001) suppressed inflammatory mediators including cyclooxygenase (COX-2), prostaglandin E2 (PGE2) and nuclear factor kappa B (NF-κB) in the serum and hepatic tissue. Furthermore, curcumae increased the gut microbial diversity and richness and decreased the relative abundance of genus Mucispirillum and Clostridium , respectively. Conclusion: Curcumae prevents HFD-induced inflammation during the hepatic carcinoma by modulating the oxidative stress, inflammatory reaction and gut microbiota. Keywords: curcumae, hepatic cellular carcinoma, gut microbiota, inflammation, antioxidant NAFLD commonly affects the vital organ such as hepatic tissue. In China, NAFLD is a common disease that affects women, men, children and older people. 1 According to the reports, 3% cases of NAFLD can boost during the inflammatory stage, which can further induce liver cirrhosis and finally cause liver failure and end-stage liver disease including hepatocellular carcinoma (primary liver cancer). 1,2 At that time, only liver transplantation was the only option to treat the disease. Currently, both death rate and incidence of HCC are greater in China. In China, the incidence rate of HCC is 40 in males and 15.3 in females per 1,00,000 and the mortality rate 37.4 in males and 14.3 in females per 1,00,000, respectively. 3 The incidence of NAFLD between normal and obese people has been reported to be 25% and 67.5%, respectively. Furthermore, NAFLD has been related to changes in gut microbiota, plays a key role in the progression of a chronic low-grade inflammatory state in the host, and promotes the growth of NASH and HCC. 1,2 Studies suggest that HCC patients suffering from NAFLD have more complex tumor and have shorter survival duration. Due to the high mortality rate and poor prognosis, no effective therapeutics were available for treating HCC, which reduce the progression and expansion of HCC, so it is necessary to scrutinize the potential chemotherapeutics for treating HCC. 1,2,4 HCC is the world's fifth most common cancer, and it ranks third in terms of deaths among all cancers. 5,6 It is well known that chronic inflammation induced by biological, physical factors and chemical is commonly observed in human cancers. Studies suggest that the primary liver cancer (70–90%) is considered the HCC. 7,8 Hepato-carcinogenesis is closely associated with liver cirrhosis, which grow a -Abstract Truncated-

immunology